<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03526445</url>
  </required_header>
  <id_info>
    <org_study_id>H-18003696</org_study_id>
    <nct_id>NCT03526445</nct_id>
  </id_info>
  <brief_title>Hepatic Metabolic Changes in Response to Glucagon Infusion</brief_title>
  <official_title>Hepatic Metabolic Changes in Response to Glucagon Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate how exogenously administered glucagon affects
      hepatic lipid, glucose and protein metabolism as well as appetite, food intake and resting
      energy expenditure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most research has focused on the role of the pancreatic hormone, insulin, and insulin
      signalling (or lack of) in the development of NAFLD. However, increasing evidence suggest
      that the other major gluco-regulatory pancreatic hormone glucagon is also implicated in lipid
      metabolism and recent human data from studies investigating the effect of glucagon receptor
      antagonism suggest that glucagon signalling may be essential for maintaining a fat-free
      liver. This, combined with observations of increased degree of hepatic steatosis in patients
      after total pancreatectomy, who are devoid of pancreatic glucagon and typically are lean and
      peripherally insulin sensitive, suggests that glucagon may play a hitherto unrecognised role
      in the pathophysiology of NAFLD.

      The hypothesis of the study is that exogenously delivered glucagon will drive hepatic
      metabolism in a lipolytic direction and increase resting energy expenditure without affecting
      appetite and food intake.

      The acute effects of exogeneous glucagon infusion on hepatic lipid metabolism will be
      evaluated in patients after total pancreatectomy (no endogenous pancreatic hormones), in
      patients with type 1 diabetes (no endogenous insulin production) and in healthy controls
      (preserved endogenous pancreatic hormones).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Actual">June 12, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic lipid metabolism</measure>
    <time_frame>-120,-30,-15,0,30,60,90,120,135,150 minutes</time_frame>
    <description>evaluated using isotopic labelled tracer kinetics: lipolysis, ketogenesis, very low-density lipoprotein (VLDL) secretion and free fatty acid (FFA) re-esterification rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of lipids</measure>
    <time_frame>0, 60,150 minutes</time_frame>
    <description>Total cholesterol, VLDL, LDL, HDL, FFA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of amino acids</measure>
    <time_frame>0, 60, 120, 150 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of fibroblast growth factor 21 (FGF-21)</measure>
    <time_frame>-120,0,150 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous glucose production</measure>
    <time_frame>-120,-30,-15,0,30,60,90,120,135,150 minutes</time_frame>
    <description>Measured by glucose tracer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in resting energy expenditure and oxidation rate</measure>
    <time_frame>0, 150 minutes</time_frame>
    <description>Measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food intake</measure>
    <time_frame>30 minutes (150-180) minutes</time_frame>
    <description>Ad libitum meal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in appetite sensation</measure>
    <time_frame>0,30,60,90,120,150 minutes</time_frame>
    <description>Visual analogue scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Total Pancreatectomy</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Glucagon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 hours i.v. infusion of Glucagon (4 ng/kg/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 hours i.v. infusion of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Glucagon (4 ng/kg/min)</description>
    <arm_group_label>Glucagon</arm_group_label>
    <other_name>GlucaGen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pancreatectomised patients

          -  Patients who have undergone total pancreatectomy

          -  Caucasian between 30-80

          -  Blood haemoglobin &gt;7.0 mmol/l for males and &gt;6.5 mmol/l for females

          -  Informed consent

        Patients with type 1 diabetes

          -  Patients with C-peptide negative type 1 diabetes

          -  Caucasian between 30-80

          -  Blood haemoglobin &gt;7.0 mmol/l for males and &gt;6.5 mmol/l for females

          -  Informed consent

        Healthy controls

          -  Normal fasting plasma glucose (&lt; 7 mmol/l) and normal HbA1c (&lt; 6.5 %) (30,31)

          -  Normal blood haemoglobin (&gt;8.3 mmol/l for males and &gt;7.3 mmol/l for females)

          -  Caucasian between 30-80

          -  Informed consent

        Exclusion Criteria:

        All subjects

          -  Inflammatory bowel disease

          -  Gastrointestinal resection (other than the gastro-duodenectomy performed in connection
             with total pancreatectomy) and/or ostomy

          -  Nephropathy (eGFR &lt; 60 ml/min/1.73 mÂ² and/or urine albumin &gt; 20 mg/L)

          -  Known liver disease (excluding non-alcoholic fatty liver disease)

          -  Severe lung disease

          -  Pregnancy and/or breastfeeding

          -  Uncontrolled hypertension and/or significant cardiovascular disease

          -  Treatment with drugs with potential steatogenic side-effects within three months prior
             to inclusion

          -  Alcohol consumption above 21 units/week for men and 14 units/week for women

          -  Any condition that the investigator feels would interfere with the safety of the trial
             participation or the safety of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip Krag Knop, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 3, 2018</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2018</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucagon</keyword>
  <keyword>Stable isotope</keyword>
  <keyword>Energy expenditure</keyword>
  <keyword>Lipid metabolism</keyword>
  <keyword>Glucose metabolism</keyword>
  <keyword>Appetite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

